Login to Your Account

Graybug nets new funds to tackle wet AMD with sustained-release tech

By Michael Fitzhugh
Staff Writer

Tuesday, March 10, 2015
Graybug Inc., a spinout of Johns Hopkins University's Wilmer Eye Institute that's developing an experimental microparticle drug for wet age-related macular degeneration, has closed a $1.74 million series A2 financing to help advance a preclinical drug and further prove its sustained-release technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription